Stocks Health care PASG
NASDAQ · Health carePassage BIO, Inc. (PASG)
It posted a net loss of $36.1M. At June 30, 2026 it held $24.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Passage BIO, Inc. does
Passage BIO, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PASG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$45.5M | -$14.35 | n/a |
| 2024 | n/a | -$64.8M | -$21.04 | -$48M |
| 2023 | n/a | -$102.1M | -$36.57 | n/a |
| 2022 | n/a | -$136.1M | -$49.16 | n/a |
| 2021 | n/a | -$185.4M | -$68.43 | n/a |
| 2020 | n/a | -$112.2M | -$57.22 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Passage BIO, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026
- September 3, 2026
- September 3, 2026Form 425 filing 425
- September 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- July 22, 2026Form 425 filing 425
- July 21, 2026
- July 2, 2026Activist stake (5% or more) SCHEDULE 13D
- June 25, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Passage BIO, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 25, 2026 | Lynx1 Capital Management LP10% owner | Boughtindirect | 50,055 | $206.1K |
Who owns PASG
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lynx1 Capital Management LP13D, may seek influence with 1 related filers | 21% | July 2, 2026 |
| Baselake Partners, LP13G, passive with 2 related filers | 7.3% | June 25, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 673,759 shares in total, about $3.2M at the last price.
| Holder | Shares |
|---|---|
| Lynx1 Capital Management LP10% owner | 673,759673,759 held indirectly |
Questions about PASG
What does Passage BIO, Inc. do?
Passage BIO, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PASG.
Is Passage BIO, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $36.1M.
When did Passage BIO, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger registration (amended) from September 21, 2026.
Similar companies
Compare PASG with
Follow PASG
Get an email when Passage BIO, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PASG: get an email when it filesWhere the numbers come from
Financial figures are the values Passage BIO, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.